The Effects of Interval Resistance-Aerobic Training and Fisetin Supplementation on Asprosin and Selected Adipokines in Obese Men: A Double-Blind Randomized Control Trial.

The training plus fisetin (TF) group achieved the greatest reductions in asprosin levels among all groups.

• Interventions exerted a highly significant effect on asprosin: F(3, 55) = 36.047, p < 0.001, ηp2 = 0.663
• The TF group experienced a -60.71% reduction in asprosin levels
• Analysis was conducted via ANCOVA with Bonferroni post hoc tests following intention-to-treat (ITT) principles
• 60 sedentary obese men (BMI < 30 kg/m2) were randomized across four groups: placebo (P), fisetin (F), training-placebo (TP), and training plus fisetin (TF)

The training plus fisetin (TF) group achieved the greatest reductions in MCP-1 levels among all groups.

• Interventions exerted a highly significant effect on MCP-1: F(3, 55) = 29.570, p < 0.001, ηp2 = 0.617
• The TF group experienced a -46.50% reduction in MCP-1 levels
• MCP-1 was identified as a primary outcome measure alongside asprosin and adiponectin

Adiponectin levels increased significantly in both the training-placebo and training plus fisetin groups.

• Significant increases in adiponectin were observed in the TP group (29.38%) and TF group (27.67%), both p < 0.05
• Adiponectin was a primary outcome measure in the study
• The fisetin-only (F) group results for adiponectin were not reported as statistically significant

Leptin changes were statistically significant only in the training plus fisetin group relative to the placebo group.

• Changes in leptin were statistically significant only in the TF group relative to placebo (p = 0.049)
• Leptin was a secondary outcome measure
• The TP and F groups did not show statistically significant changes in leptin compared to placebo

Body weight was significantly reduced in the TF, TP, and fisetin groups compared to the placebo group.

• Significant difference in mean body weight was observed between groups: F(3, 55) = 9.444, p < 0.001, ηp2 = 0.340
• Bonferroni post hoc tests confirmed that TF, TP, and F groups all achieved significant weight loss compared to placebo
• BMI showed a significant inter-group difference (p = 0.021), but only the TF group reached statistically significant BMI reduction compared to placebo (p = 0.024; 95% CI [-3.760, -0.172])

The training plus fisetin group demonstrated significant improvements in all lipid profile markers, while the placebo group experienced deterioration.

• The TF group achieved statistically significant reductions in LDL-C, triglycerides (TG), and total cholesterol (TC) (p < 0.001) and a significant elevation in HDL-C
• Post hoc analyses confirmed robust statistical differences in all lipid parameters for both TF and TP groups compared to placebo (p < 0.05)
• The placebo group experienced deterioration characterized by a significant increase in LDL-C (p = 0.027) and a significant decline in HDL-C concentrations (p = 0.006)
• Lipid profile was a secondary outcome measure

The study employed a 12-week interval resistance plus progressive aerobic training protocol combined with 200 mg/day fisetin supplementation.

• Training consisted of thrice-weekly interval resistance training: eight exercises, 3 × 13 reps at 60% 1RM with 20% 1RM active rest
• Resistance training was immediately followed by staged aerobic bouts at 50-70% HRmax
• Fisetin supplementation dose was 200 mg/day over 12 weeks
• The study was a double-blind, parallel-group randomized controlled trial with 60 sedentary obese men
• Four groups were used: control-placebo (P), fisetin (F), training-placebo (TP), and training plus fisetin (TF)

The authors identify asprosin as a potential modulator in metabolic risk reduction, while acknowledging that direct mechanistic assays were not conducted.

• The paper states these implications 'remain hypothetical' since 'direct mechanistic assays were not conducted'
• The authors call for 'future research employing molecular readouts to confirm the underlying pathways involved'
• Asprosin had the largest effect size among the primary outcomes (ηp2 = 0.663)